8月20日，远大医药（00512）股价盘中大涨5.27%，引发市场关注。这一涨幅与公司近期公布的2025年中期业绩密切相关。
根据财报，远大医药2025年上半年营收再创新高，达到约61.1亿港元，其中创新及壁垒产品收入占比约51%，同比提升近15个百分点。若剔除集采及汇率影响，公司收入同比增长约13%。期内公司净利润约11.7亿港元。值得注意的是，公司研发及项目投入总计约10.2亿港元，共实现38项重大里程碑进展，显示出强劲的创新动力。
远大医药在核药抗肿瘤诊疗领域表现尤为亮眼，该板块收入同比增长近106%，达到4.2亿港元。此外，公司在呼吸及危重症、创新眼药、心脑血管急救等战略方向也取得显著进展。特别是自主研发的全球创新产品STC3141在脓毒症治疗领域的突破性进展，有望为公司未来发展开辟新的增长空间。这些积极因素共同推动了投资者对远大医药未来发展前景的信心，从而带动股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.